BioMarin Pharmaceutical Inc (BMRN) stock
BMRNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 8/3091% above fair value
$57.23+0.53 (+0.93%)
Close on Nov 13, 2026Market cap $11.08BP/E 150.6Yield –
BioMarin Pharmaceutical gross margin
Gross margin is gross profit as a percentage of revenue.
BioMarin Pharmaceutical's gross margin for the twelve months ending Jun 30, 2026 was 76.1%. For fiscal 2025 it was 77.7%, against 79.7% the year before. The highest annual figure on record is 83.9% in fiscal 2013.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 77.7% | −1.9 |
| FY2024 | Dec 31, 2024 | 79.7% | +1.7 |
| FY2023 | Dec 31, 2023 | 78.0% | +2.0 |
| FY2022 | Dec 31, 2022 | 76.0% | +1.5 |
| FY2021 | Dec 31, 2021 | 74.5% | +2.7 |
| FY2020 | Dec 31, 2020 | 71.8% | −7.1 |
| FY2019 | Dec 31, 2019 | 78.9% | +0.0 |
| FY2018 | Dec 31, 2018 | 78.9% | −2.7 |
| FY2017 | Dec 31, 2017 | 81.6% | +0.4 |
| FY2016 | Dec 31, 2016 | 81.2% | −1.7 |
| FY2015 | Dec 31, 2015 | 82.9% | −0.8 |
| FY2014 | Dec 31, 2014 | 83.7% | −0.2 |
| FY2013 | Dec 31, 2013 | 83.9% | +2.2 |
| FY2012 | Dec 31, 2012 | 81.7% | +0.7 |
| FY2011 | Dec 31, 2011 | 81.0% | −0.4 |
| FY2010 | Dec 31, 2010 | 81.3% | +1.6 |
| FY2009 | Dec 31, 2009 | 79.7% | −2.6 |
| FY2008 | Dec 31, 2008 | 82.3% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 79.5% | −2.3 |
| Q1 FY2026 | Mar 31, 2026 | 74.6% | −5.1 |
| Q4 FY2025 | Dec 31, 2025 | 68.5% | −13.3 |
| Q3 FY2025 | Sep 30, 2025 | 82.0% | +7.2 |
| Q2 FY2025 | Jun 30, 2025 | 81.8% | +0.1 |
| Q1 FY2025 | Mar 31, 2025 | 79.7% | −1.0 |
| Q4 FY2024 | Dec 31, 2024 | 81.8% | +3.1 |
| Q3 FY2024 | Sep 30, 2024 | 74.7% | −3.2 |
| Q2 FY2024 | Jun 30, 2024 | 81.7% | +3.6 |
| Q1 FY2024 | Mar 31, 2024 | 80.7% | +3.4 |
| Q4 FY2023 | Dec 31, 2023 | 78.7% | +5.9 |
| Q3 FY2023 | Sep 30, 2023 | 78.0% | +1.0 |
| Q2 FY2023 | Jun 30, 2023 | 78.1% | +1.1 |
| Q1 FY2023 | Mar 31, 2023 | 77.3% | −0.2 |
| Q4 FY2022 | Dec 31, 2022 | 72.7% | −0.7 |
| Q3 FY2022 | Sep 30, 2022 | 77.0% | +2.3 |
| Q2 FY2022 | Jun 30, 2022 | 76.9% | +2.3 |
| Q1 FY2022 | Mar 31, 2022 | 77.5% | +2.2 |
| Q4 FY2021 | Dec 31, 2021 | 73.4% | +1.3 |
| Q3 FY2021 | Sep 30, 2021 | 74.7% | +14.3 |
| Q2 FY2021 | Jun 30, 2021 | 74.7% | −2.5 |
| Q1 FY2021 | Mar 31, 2021 | 75.3% | −2.5 |
| Q4 FY2020 | Dec 31, 2020 | 72.1% | −6.8 |
| Q3 FY2020 | Sep 30, 2020 | 60.4% | −18.6 |
| Q2 FY2020 | Jun 30, 2020 | 77.2% | −2.8 |
| Q1 FY2020 | Mar 31, 2020 | 77.8% | +0.1 |
| Q4 FY2019 | Dec 31, 2019 | 78.9% | +0.1 |
| Q3 FY2019 | Sep 30, 2019 | 79.0% | −0.9 |
| Q2 FY2019 | Jun 30, 2019 | 80.0% | +1.2 |
| Q1 FY2019 | Mar 31, 2019 | 77.7% | −0.2 |
| Q4 FY2018 | Dec 31, 2018 | 78.8% | −0.0 |
| Q3 FY2018 | Sep 30, 2018 | 79.9% | −2.3 |
| Q2 FY2018 | Jun 30, 2018 | 78.8% | −3.5 |
| Q1 FY2018 | Mar 31, 2018 | 78.0% | −5.6 |
| Q4 FY2017 | Dec 31, 2017 | 78.8% | +0.2 |
| Q3 FY2017 | Sep 30, 2017 | 82.2% | +0.3 |
| Q2 FY2017 | Jun 30, 2017 | 82.3% | – |
| Q1 FY2017 | Mar 31, 2017 | 83.5% | – |
| Q4 FY2016 | Dec 31, 2016 | 78.6% | – |
| Q3 FY2016 | Sep 30, 2016 | 81.9% | – |
See a number that looks wrong?